News & Updates
Filter by Specialty:
Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.
Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
10 Feb 2023Hormone therapies up ILD events in men with prostate cancer
Hormone therapy drugs, such as bicalutamide, flutamide, nilutamide, goserelin, degarelix, and apalutamide, appear to increase the likelihood of developing interstitial lung disease (ILD) events in patients with prostate cancer, reports a study.
Hormone therapies up ILD events in men with prostate cancer
04 Feb 2023Does molnupiravir improve outcomes in vaccinated COVID-19 patients?
The addition of molnupiravir to usual care does not reduce hospitalization or death in vaccinated, community-dwelling individuals at high risk of serious outcomes of COVID-19, results of the UK-based PANORAMIC trial showed. However, it may provide other benefits such as reducing time to recovery.
Does molnupiravir improve outcomes in vaccinated COVID-19 patients?
03 Feb 2023Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?
Hypofractionated radiotherapy (HFRT) is not superior to conventionally fractionated radiotherapy (CFRT) in providing survival benefits to patients with stage I nonsmall cell lung cancer (NSCLC), but HFRT is preferable due to its convenience and lower costs, according to a study.
Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?
03 Feb 2023COVID-19 vaccines partially effective against Omicron BA.2 infection in children and adolescents in HK
According to a retrospective, territory-wide, case-based study, the mRNA-based BNT162b2 vaccine and inactivated CZ02 vaccine were partially effective against SARS-CoV-2 infection in children and adolescents during the Omicron BA.2 wave in Hong Kong.